Teruna J Siahaan

List of Publications by Year
in descending order

154	4,680	109321	123424
papers	citations	35 h-index	61 g-index

160	160	160	5395
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Enhancing Intestinal Absorption of a Model Macromolecule via the Paracellular Pathway using E-Cadherin Peptides. Journal of Pharmaceutical Sciences, 2021, 110, 2139-2148.	3.3	2
2	Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice. Molecular Pharmaceutics, 2020, 17, 404-416.	4.6	14
3	Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Scientific Reports, 2020, 10, 11292.	3.3	160
4	Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice. Medical Research Archives, 2020, 8, .	0.2	14
5	Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides. Pharmaceutics, 2019, 11, 568.	4.5	14
6	In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes. Molecular Pharmaceutics, 2019, 16, 4878-4889.	4.6	9
7	Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors. Pharmaceutics, 2019, 11, 481.	4.5	13
8	Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein. Biochemical and Biophysical Research Communications, 2019, 515, 99-103.	2.1	14
9	Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model. European Journal of Pharmacology, 2019, 853, 264-274.	3.5	15
10	Methods of Delivering Molecules Through the Blood-Brain Barrier for Brain Diagnostics and Therapeutics. Neuromethods, 2019, , 9-43.	0.3	2
11	Protein PEGylation for cancer therapy: bench to bedside. Journal of Cell Communication and Signaling, 2019, 13, 319-330.	3.4	76
12	Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases. Current Topics in Medicinal Chemistry, 2018, 17, 3425-3443.	2.1	13
13	Probing the interaction between cHAVc3 peptide and the EC1 domain of E-cadherin using NMR and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2017, 35, 92-104.	3.5	17
14	Synthesis of a Bifunctional Peptide Inhibitorâ€“IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis. Bioconjugate Chemistry, 2017, 28, 1867-1877.	3.6	8
15	Peptides and Drug Delivery. Advances in Experimental Medicine and Biology, 2017, 1030, 167-184.	1.6	12
16	Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. Thrombosis and Haemostasis, 2017, 117, 339-348.	3.4	28
17	Improving Brain Delivery of Biomolecules via BBB Modulation in Mouse and Rat: Detection using MRI, NIRF, and Mass Spectrometry. Nanotheranostics, 2017, 1, 217-231.	5.2	26
18	Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis. Journal of Vascular Research, 2016, 53, 186-195.	1.4	8

#	Article	IF	Citations
19	A Tribute to Ronald T. Borchardtâ€"Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. Journal of Pharmaceutical Sciences, 2016, 105, 370-385.	3.3	4
20	Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain. Journal of Pharmaceutical Sciences, 2016, 105, 797-807.	3.3	30
21	Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LCâ€"MS/MS and Gd-DTPA Using Magnetic Resonance Imaging. Molecular Pharmaceutics, 2016, 13, 379-390.	4.6	17
22	Modulation of Intercellular Junctions by Cyclic-ADT Peptides as a Method to Reversibly Increase Bloodâ€"Brain Barrier Permeability. Journal of Pharmaceutical Sciences, 2015, 104, 1065-1075.	3.3	39
23	Influence of particle size, an elongated particle geometry, and adjuvants on dendritic cell activation. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 542-549.	4.3	21
24	1H, 13C and 15N backbone assignment of the EC-1 domain of human E-cadherin. Biomolecular NMR Assignments, 2015, 9, 31-35.	0.8	4
25	Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14008.	4.1	35
26	Immune Tolerance Induction against Experimental Autoimmune Encephalomyelitis (EAE) Using A New PLP-B7AP Conjugate that Simultaneously Targets B7/CD28 Costimulatory Signal and TCR/MHC-II Signal. Journal of Multiple Sclerosis, 2014, 02, .	0.1	10
27	Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced Arthritis. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	6
28	Pathways and progress in improving drug delivery through the intestinal mucosa and bloodâ€"brain barriers. Therapeutic Delivery, 2014, 5, 1143-1163.	2.2	99
29	Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis. AAPS Journal, 2014, 16, 1185-1193.	4.4	26
30	Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis. AAPS Journal, 2014, 16, 1204-1213.	4.4	26
31	Hyaluronic Acid Graft Polymers Displaying Peptide Antigen Modulate Dendritic Cell Response in Vitro. Molecular Pharmaceutics, 2014, 11, 367-373.	4.6	16
32	Modulation of Bloodâ€"Brain Barrier Permeability in Mice Using Synthetic E-Cadherin Peptide. Molecular Pharmaceutics, 2014, 11, 974-981.	4.6	42
33	Abstract 191: Endothelial Dysfunction Potentiates Deep Venous Thrombosis in a Mouse Model of Sepsis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
34	Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor. Journal of Neuroimmunology, 2013, 263, 20-27.	2.3	17
35	Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. Journal of Controlled Release, 2013, 168, 334-340.	9.9	30
36	Vaccinelike and Prophylactic Treatments of EAE with Novel I-Domain Antigen Conjugates (IDAC): Targeting Multiple Antigenic Peptides to APC. Molecular Pharmaceutics, 2013, 10, 297-306.	4.6	4

#	Article	IF	Citations
37	Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2013, 172, 23-36.	2.6	9
38	Peptide Delivery. , 2013, , 1702-1710.		6
39	Cadherin peptideâ€induced enhancement of blood brain barrier (BBB) permeability. FASEB Journal, 2013, 27, 668.3.	0.5	0
40	I-Domain-Antigen Conjugate (IDAC) for Delivering Antigenic Peptides to APC: Synthesis, Characterization, and in Vivo EAE Suppression. Bioconjugate Chemistry, 2012, 23, 509-517.	3.6	6
41	Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics, 2012, 9, 979-985.	4.6	65
42	Suppression of EAE and prevention of bloodâ€“brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor. Neuropharmacology, 2012, 62, 1874-1881.	4.1	28
43	Methotrexate (MTX)â€“cIBR Conjugate for Targeting MTX to Leukocytes: Conjugate Stability and In Vivo Efficacy in Suppressing Rheumatoid Arthritis. Journal of Pharmaceutical Sciences, 2012, 101, 3275-3291.	3.3	13
44	Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clinical Immunology, 2012, 144, 127-138.	3.2	30
45	Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue. International Journal of Pharmaceutics, 2012, 431, 16-25.	5.2	6
46	Peptideâ€mediated targeted drug delivery. Medicinal Research Reviews, 2012, 32, 637-658.	10.5	122
47	Antigenâ€specific blocking of CD4â€Specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Medicinal Research Reviews, 2012, 32, 727-764.	10.5	28
48	Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response. ACS Nano, 2011, 5, 1693-1702.	14.6	22
49	Rapid Identification of Fluorochrome Modification Sites in Proteins by LC ESI-Q-TOF Mass Spectrometry. Bioconjugate Chemistry, 2011, 22, 1330-1336.	3.6	15
50	Enhancement of Drug Absorption through the Bloodâ^'Brain Barrier and Inhibition of Intercellular Tight Junction Resealing by E-Cadherin Peptides. Molecular Pharmaceutics, 2011, 8, 239-249.	4.6	44
51	Calcium Condensed LABL-TAT Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells. Molecular Pharmaceutics, 2011, 8, 788-798.	4.6	38
52	Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes. Theranostics, 2011, 1, 277-289.	10.0	13
53	Controlling Ligand Surface Density Optimizes Nanoparticle Binding to ICAM-1. Journal of Pharmaceutical Sciences, 2011, 100, 1045-1056.	3.3	78
54	Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery, 2011, 2, 873-889.	2.2	20

#	Article	IF	Citations
55	Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model. Journal of Controlled Release, 2010, 141, 145-152.	9.9	25
56	A Peptide from the Betaâ€strand Region of CD2 Protein that Inhibits Cell Adhesion and Suppresses Arthritis in a Mouse Model. Chemical Biology and Drug Design, 2010, 76, 234-244.	3.2	9
57	Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor: Structure Optimization and Pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 1136-1145.	2.5	23
58	cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells. Molecular Pharmaceutics, 2010, 7, 146-155.	4.6	14
59	Effect of Modification of the Physicochemical Properties of ICAM-1-Derived Peptides on Internalization and Intracellular Distribution in the Human Leukemic Cell Line HL-60. Molecular Pharmaceutics, 2009, 6, 396-406.	4.6	11
60	ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. European Journal of Pharmaceutical Sciences, 2009, 37, 141-150.	4.0	161
61	Evaluation of the physical stability of the EC5 domain of E-cadherin: Effects of pH, temperature, ionic strength, and disulfide bonds. Journal of Pharmaceutical Sciences, 2009, 98, 63-73.	3.3	20
62	The Role of Covalent Dimerization on the Physical and Chemical Stability of the EC1 Domain of Human E-Cadherin. Journal of Pharmaceutical Sciences, 2009, 98, 3562-3574.	3.3	11
63	Solution structure of a novel Tâ€cell adhesion inhibitor derived from the fragment of ICAMâ€1 receptor: Cyclo(1,8)â€Cysâ€Proâ€Argâ€Glyâ€Glyâ€Serâ€Valâ€Cys. Biopolymers, 2009, 91, 633-641.	2.4	3
64	Adhesion of pancreatic beta cells to biopolymer films. Biopolymers, 2009, 91, 676-685.	2.4	44
65	Characterization of Multiple Stable Conformers of the EC5 Domain of Eâ€cadherin and the Interaction of EC5 with Eâ€cadherin Peptides. Chemical Biology and Drug Design, 2009, 73, 584-598.	3.2	11
66	The Role of Thiols and Disulfides on Protein Stability. Current Protein and Peptide Science, 2009, 10, 614-625.	1.4	317
67	Structural Modifications of ICAMâ€1 Cyclic Peptides to Improve the Activity to Inhibit Heterotypic Adhesion of T cells. Chemical Biology and Drug Design, 2008, 72, 27-33.	3.2	10
68	Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clinical Immunology, 2008, 129, 69-79.	3.2	26
69	PLGA Nanoparticleâ€"Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1. Bioconjugate Chemistry, 2008, 19, 145-152.	3.6	176
70	Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 879-886.	2.5	40
71	Mechanism of Internalization of an ICAM-1-Derived Peptide by Human Leukemic Cell Line HL-60: Influence of Physicochemical Properties on Targeted Drug Delivery. Molecular Pharmaceutics, 2007, 4, 749-758.	4.6	20
72	Sequence Recognition of Î±â€LFAâ€1â€derived Peptides by ICAMâ€1 Cell Receptors: Inhibitors of Tâ€cell Adhesion. Chemical Biology and Drug Design, 2007, 70, 237-246.	3.2	14

#	Article	IF	Citations
73	Suppression of Type 1 Diabetes in NOD Mice by Bifunctional Peptide Inhibitor: Modulation of the Immunological Synapse Formation. Chemical Biology and Drug Design, 2007, 70, 227-236.	3.2	29
74	ICAMâ€1 Peptide Inhibitors of Tâ€cell Adhesion bind to the allosteric site of LFAâ€1. An NMR Characterization. Chemical Biology and Drug Design, 2007, 70, 347-353.	3.2	23
75	ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization. Chemical Biology and Drug Design, 2007, .	3.2	0
76	Effects of Amino Acid Chirality and the Chemical Linker on the Cell Permeation Characteristics of Cyclic Prodrugs of Opioid Peptides. Journal of Medicinal Chemistry, 2006, 49, 1261-1270.	6.4	16
77	Characterization of Binding Properties of ICAM-1 Peptides to LFA-1: Inhibitors of T-cell Adhesion. Chemical Biology and Drug Design, 2006, 68, 20-28.	3.2	20
78	Cell Adhesion Molecules for Targeted Drug Delivery. Journal of Pharmaceutical Sciences, 2006, 95, 1856-1872.	3.3	108
79	Synthesis and chemical stability of a disulfide bond in a model cyclic pentapeptide: Cyclo(1,4)â€Cysâ€Glyâ€Pheâ€Cysâ€Glyâ€OH. Journal of Pharmaceutical Sciences, 2006, 95, 2222-2234.	3.3	18
80	Inhibition of E-Cadherin-Mediated Homotypic Adhesion of Caco-2 Cells: A Novel Evaluation Assay for Peptide Activities in Modulating Cell-Cell Adhesion. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 309-316.	2.5	24
81	VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2006, 290, G648-G654.	3.4	72
82	Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery. Current Pharmaceutical Design, 2006, 12, 2813-2824.	1.9	40
83	Oral Protein and Peptide Drug Delivery. , 2005, , 189-200.		9
84	Parenteral Formulation for Peptides, Proteins, and Monoclonal Antibodies Drugs: A Commercial Development Overview. , 2005, , 321-339.		0
85	Factors That Impact the Developability of Drug Candidates: An Overview. , 2005, , 1-14.		7
86	Metabolic Activation and Drug Targeting. , 2005, , 201-244.		0
87	Ultrasound-Mediated Drug Delivery. , 2005, , 245-278.		4
88	Polycationic Peptides and Proteins in Drug Delivery: Focus on Nonclassical Transport. , 2005, , 279-304.		0
89	Gene Therapy and Gene Delivery. , 2005, , 305-319.		2
90	Antibody-Directed Drug Delivery. , 2005, , 363-379.		1

#	Article	IF	Citations
91	Efflux Transporters in Drug Excretion. , 2005, , 381-410.		3
92	Regulatory and Intellectual Property Issues in Drug Delivery Research. , 2005, , 435-442.		1
93	Pathways for Drug Delivery to the Central Nervous System. , 2005, , 29-56.		3
94	Targeted Bioavailability: A Fresh Look at Pharmacokinetic and Pharmacodynamic Issues in Drug Delivery. , 2005, , 73-82.		0
95	Presystemic and First-Pass Metabolism. , 2005, , 83-101.		0
96	Cell Culture Models for Drug Transport Studies. , 2005, , 103-124.		0
97	Receptor-Mediated Drug Delivery. , 2005, , 167-187.		3
98	Deamidation of model Î²-turn cyclic peptides in the solid state. Journal of Pharmaceutical Sciences, 2005, 94, 2616-2631.	3.3	10
99	Î±L-Integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium. American Journal of Physiology - Renal Physiology, 2005, 288, G67-G73.	3.4	20
100	Physicochemical Properties, Formulation, and Drug Delivery. , 2005, , 57-71.		1
101	Liposomes as Drug Delivery Vehicles. , 2005, , 411-434.		7
102	Pulmonary Drug Delivery: Pharmaceutical Chemistry and Aerosol Technology. , 2005, , 341-361.		10
103	Modulation of Cell Adhesion Molecules in Various Epithelial Cell Lines after Treatment with PP2â€. Molecular Pharmaceutics, 2005, 2, 170-184.	4.6	8
104	Prodrug Approaches to Drug Delivery. , 2005, , 125-165.		6
105	Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery. , 2005, , 15-27.		4
106	Design, structure and biological activity of Î²-turn peptides of CD2 protein for inhibition of T-cell adhesion. FEBS Journal, 2004, 271, 2873-2886.	0.2	14
107	Reductive Alkylation of Lipase: Experimental and Molecular Modeling Approaches. Applied Biochemistry and Biotechnology, 2004, 118, 011-020.	2.9	6
108	Effects of An E-cadherin-Derived Peptide on the Gene Expression of Caco-2 Cells. Pharmaceutical Research, 2004, 21, 2085-2094.	3.5	6

#	Article	IF	Citations
109	Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1399-1402.	2.2	22
110	Expression, purification, and structural study of the EC4 domain of E-cadherin. Protein Expression and Purification, 2004, 33, 72-79.	1.3	3
111	Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharmaceutical Research, 2003, 20, 1523-1532.	3.5	35
112	Synthesis and comparison of physicochemical, transport, and antithrombic properties of a cyclic prodrug and the parent RGD peptidomimetic. Tetrahedron, 2003, 59, 2861-2869.	1.9	5
113	Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides, 2003, 24, 487-501.	2.4	126
114	A Peptide Derived from LFA-1 Protein that Modulates T-cell Adhesion Binds to Soluble ICAM-1 Protein. Journal of Biomolecular Structure and Dynamics, 2003, 20, 635-644.	3.5	7
115	Structural and ICAM-1-Docking Properties of a Cyclic Peptide from the I-domain of LFA-1: An inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion. Journal of Biomolecular Structure and Dynamics, 2002, 19, 789-799.	3.5	19
116	Disulfide Bond Formation Promotes the cis- and trans-Dimerization of the E-cadherin-derived First Repeat. Journal of Biological Chemistry, 2002, 277, 16002-16010.	3.4	18
117	Rapid Determination of Substrate Specificity of Clostridium histolyticum Î²-Collagenase Using an Immobilized Peptide Library. Journal of Biological Chemistry, 2002, 277, 8366-8371.	3.4	20
118	Synthesis of Cyclic Prodrugs of Aggrastat and Its Analogue with a Modified Phenylpropionic Acid Linker. Organic Letters, 2002, 4, 549-552.	4.6	12
119	Localized production of human E-cadherin-derived first repeat in Escherichia coli. Protein Expression and Purification, 2002, 26, 449-454.	1.3	6
120	Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews, 2002, 22, 146-167.	10.5	339
121	Steric hindrance is a key factor in the coupling reaction of (acyloxy) alkyl-Î±-halides with phenols to make a new promoiety for prodrugs. Tetrahedron Letters, 2002, 43, 577-579.	1.4	13
122	Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation. Bioorganic Chemistry, 2002, 30, 285-301.	4.1	16
123	Synthesis and stability study of a modified phenylpropionic acid linker-based esterase-sensitive prodrug. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3439-3442.	2.2	8
124	N-cadherin involvement in the heterotypic adherence of malignant T-cells to epithelia. Molecular and Cellular Biochemistry, 2002, 233, 1-8.	3.1	6
125	A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics. Pharmaceutical Research, 2002, 19, 794-801.	3.5	25
126	Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin. Pharmaceutical Research, 2002, 19, 1170-1179.	3.5	51

#	Article	IF	Citations
127	Synergistic inhibitory activity of Î±- and Î²-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides, 2001, 22, 1955-1962.	2.4	23
128	Conjugation with L-Glutamate forin vivoBrain Drug Delivery. Journal of Drug Targeting, 2001, 9, 23-37.	4.4	11
129	Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. , 2001, 18, 329-335.		36
130	Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1. Inflammation, 2001, 25, 203-214.	3.8	28
131	Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers. Pharmaceutical Research, 2001, 18, 446-453.	3.5	55
132	Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides, 2000, 21, 1161-1167.	2.4	52
133	Solution stability of linear vs. cyclic RGD peptides. Chemical Biology and Drug Design, 1999, 53, 530-541.	1.1	160
134	Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharmaceutical Research, 1999, 16, 24-29.	3.5	43
135	Comparison of the Solution Conformations of a Cell-Adhesive Peptide LBE and its Reverse Sequence EBL. Journal of Biomolecular Structure and Dynamics, 1999, 17, 429-444.	3.5	9
136	PEPTIDES DERIVED FROM ICAM-1 AND LFA-1 MODULATE T CELL ADHESION AND IMMUNE FUNCTION IN A MIXED LYMPHOCYTE CULTURE1. Transplantation, 1999, 68, 685-692.	1.0	41
137	Derivatives of Melphalan Designed to Enhance Drug Accumulation in Cancer Cells. Journal of Drug Targeting, 1997, 4, 359-370.	4.4	16
138	Modulation of the Cellular Junction Protein E-Cadherin in Bovine Brain Microvessel Endothelial Cells by Cadherin Peptides. Drug Delivery, 1997, 4, 187-193.	5.7	24
139	Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides That Utilizes a â€œTrimethyl Lockâ€•Facilitated Lactonization Reaction. Journal of Organic Chemistry, 1997, 62, 1363-1367.	3.2	51
140	Separation and Analysis of Peptides and Proteins. Analytical Chemistry, 1997, 69, 29-58.	6.5	36
141	Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug of a Hexapeptide Using an (Acyloxy)alkoxy Promoiety. Journal of Organic Chemistry, 1997, 62, 1356-1362.	3.2	48
142	Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligandâ^'Melphalan Conjugate. Journal of Medicinal Chemistry, 1997, 40, 1726-1730.	6.4	32
143	Molecular Structure of the Apical Junction Complex and Its Contribution to the Paracellular Barrier. Journal of Pharmaceutical Sciences, 1997, 86, 977-984.	3.3	55
144	Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide. Brain Research, 1997, 747, 103-113.	2.2	50

#	Article	IF	Citations
145	Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell monolayers. Pharmaceutical Research, 1997, 14, 169-175.	3.5	83
146	The effect of beta-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharmaceutical Research, 1997, 14, 1332-1340.	3.5	75
147	Conformational analysis of cyclo(2,9)â€Acâ€QCRSVEGSCGâ€OH from the Câ€terminal loop of human growth hormone. Chemical Biology and Drug Design, 1997, 49, 15-22.	1.1	3
148	Inhibition of homotypic adhesion of Tâ€cells: secondary structure of an ICAMâ€1â€derived cyclic peptide. Chemical Biology and Drug Design, 1997, 49, 517-526.	1.1	19
149	Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharmaceutical Research, 1996, 13, 1615-1623.	3.5	62
150	The effect of conformation on membrane permeability of an acyloxyalkoxy-linked cyclic prodrug of a model hexapeptide. Pharmaceutical Research, 1996, 13, 1657-1662.	3.5	45
151	Solution Structure of a Cyclic RGD Peptide That Inhibits Platelet Aggregation. Journal of Biomolecular Structure and Dynamics, 1996, 14, 1-11.	3.5	24
152	The importance of structural factors on the rate and the extent of N,O-acyl migration in cyclic and linear peptides. Pharmaceutical Research, 1995, 12, 323-328.	3.5	17
153	Secondary Structure of the HAV Peptide Which Regulates Cadherin-Cadherin Interaction. Journal of Biomolecular Structure and Dynamics, 1995, 13, 447-455.	3.5	11
154	The aqueous conformation of cyclo(1,6)Acâ€Cysâ€Argâ€Glyâ€Aspâ€Pheâ€Penâ€NH₂. International Journal of Peptide and Protein Research, 1994, 44, 427-434.	0.1	7